User talk:Jlevi/CRISPR Therapeutics (company)

Crispr Therapeutics Plans Its First Clinical Trial for Genetic Disease (long, Wired)

Crispr Gene-Editing Upstart Editas Goes Public as Patent Battle Rages (minor, Wired)

Early Results Are Positive for Experimental CRISPR Therapies (opinion, The Scientist, Nov 2019)

US Companies Launch CRISPR Clinical Trial (opinion, The Scientist, Sep 2018)

Another CRISPR Biotech Goes Public (Sep 2016)

A troubling link has been found between a cutting-edge gene-editing technology and cancer — and it's sending biotech stocks tumbling (Business Insider, Jan 2018)

Bayer Enters CRISPR Field (The Scientist, Dec 2015)

A major gene-editing company just got $335 million to get its technology into people (Business Insider, Dec 2015)

Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In March (Motley Fool, 2020, short)

[https://www.fool.com/investing/2020/04/10/have-an-extra-1000-buy-these-2-biotech-stocks.aspx Have An Extra $1,000? Buy These 2 Biotech Stocks] (Motley Fool, April 2020, short)

CRISPR Therapeutics braces for 'severe impact' from COVID-19 crisis (Fierce Biotech, April 2020)

Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals (Reuters, June 2016, short on Vertex collab)